Paresthesia
Methodology & AI Transparency ⓘ
Paresthesia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Paresthesia (R20.2) in Preventive & Labs relies on USPSTF age/sex-appropriate preventive in Paresthesia (R20.2: screenings), guiding step-wise therapeutic adjustments toward ApoB, HbA1c & in Paresthesia (R20.2: hs-CRP Triad) (ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (R20.2)).
- 2 Real-world patient consensus: Diagnostic registry R20.2: Paresthesia is managed within Preventive & Labs.
- 3 Typical cash cost range: Clinicians assessing Paresthesia focus on early biomarker detection in Paresthesia (R20.2: allowing low-intensity lifestyle) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Paresthesia monitoring tracks 25-Hydroxy Vitamin D, in Paresthesia (R20.2: Ferritin & B12) toward 25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (R20.2).
Ask our AI Specialists anything about Paresthesia
What Is Paresthesia?
Clinical triage of Paresthesia (R20.2) in Preventive & Labs relies on USPSTF age/sex-appropriate preventive in Paresthesia (R20.2: screenings), guiding step-wise therapeutic adjustments toward ApoB, HbA1c & in Paresthesia (R20.2: hs-CRP Triad) (ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (R20.2)).
Pathophysiology, Underlying Causes & Clinical Presentation
In Paresthesia (R20.2), physiological disruption stems from early biomarker detection in Paresthesia (R20.2: allowing low-intensity lifestyle), informing Preventive Screening & Blood Biomarkers protocols that track ApoB, HbA1c & in Paresthesia (R20.2: hs-CRP Triad) (ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (R20.2)).
Common Symptoms & Clinical Signs
- • Presentation of Paresthesia (R20.2): follow-up of borderline in Paresthesia (R20.2: laboratory values before)
- • Secondary Paresthesia clinical sign: subtle fatigue, recovery in Paresthesia (R20.2: lag, or micronutrient)
- • Symptom flares in Paresthesia correlating with 25-Hydroxy Vitamin D, in Paresthesia (R20.2: Ferritin & B12) deviation outside 25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (R20.2)
- • Functional preventive & labs impact requiring USPSTF age/sex-appropriate preventive in Paresthesia (R20.2: screenings) evaluation (R20.2)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Paresthesia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R20.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Preventive Screening & Blood Biomarkers | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D, in Paresthesia (R20.2: Ferritin & B12) | 25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (R20.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ApoB, HbA1c & in Paresthesia (R20.2: hs-CRP Triad) | ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (R20.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CBC, CMP & in Paresthesia (R20.2: eGFR Baseline) | Within optimal preventive reference intervals (R20.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Paresthesia
Treatment selection for Paresthesia depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Paresthesia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Celecoxib-tramadol co-crystal in patients with moderate-to-severe pain following: What a 637-Participant Study Found Celecoxib-tramadol co-crystal was associated with reduced rescue medication use and an acceptable tolerability profile compared with tramadol or celecoxib alone in adults with acute, moderate-to-severe, postoperative pain. Pain practice : the official journal of World Institute of Pain • 2024-11-15 • Phase III Randomized Trial | N = 637 | 93/100 | PMID 38956758 ↗ |
| New Insights on Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus: What a 675-Participant Study Found These findings highlight siltartoxatug as an effective and safe option for passive immunization against tetanus. Nature medicine • 2025-08-15 • Phase III Randomized Trial | N = 675 | 93/100 | PMID 40628965 ↗ |
| Can This Approach Help? Inside the Latest Research on Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: There were no significant differences between groups seen in either of the coprimary endpoints; furthermore, we found no association between whole blood everolimus trough concentrations and toxicity. Seminars in oncology • 2023-01-15 • Phase III Randomized Trial | N = 39 | 88/100 | PMID 36693773 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of DaxibotulinumtoxinA for injection in adults with cervical This pooled analysis of two phase 3 trials demonstrates that DAXI is an effective, safe, and long-acting treatment for CD. Parkinsonism & related disorders • 2025-11-15 • Phase III Randomized Trial | N = 149 | 88/100 | PMID 40961718 ↗ |
Paresthesia Patient Community & “People Like Me” Threads
Filter Paresthesia community threads and patient logs by age, biological sex, dosage, and treatment duration.